866-997-4948(US-Canada Toll Free)

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 51 Pages

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017

Summary

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2017, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Female Contraception, Glioblastoma Multiforme (GBM), Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

Furthermore, this report also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
- The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Cytomegalovirus Envelope Glycoprotein B (gB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Cytomegalovirus Envelope Glycoprotein B (gB) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview 6
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 17
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development 19
Astellas Pharma Inc 19
Merck & Co Inc 19
Novartis AG 20
Trellis Bioscience Inc 20
Vakzine Projekt Management GmbH 20
VBI Vaccines Inc 21
Vical Inc 21
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles 23
ASP-0113 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Bispecific Monoclonal Antibody to Target CD3 and gB for Cytomegalovirus (HHV-5) Infections - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CSJ-148 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
CyMVectin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Cytomegalovirus vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
PPCM - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
TRL-345 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VBI-1501A - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
VBI-1901 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
VPM-2001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products 40
Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones 41
Featured News & Press Releases 41
Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017 41
Oct 11, 2017: VBI Vaccines to Present Phase 1 CMV vaccine data at The World Vaccine Congress Europe 2017 in Barcelona 41
Oct 10, 2017: Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial 41
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 42
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 42
Jul 27, 2017: VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine 43
May 02, 2017: VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study 44
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 44
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 45
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 45
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 46
Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 46
Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate 47
Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress 47
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Pipeline by Astellas Pharma Inc, H2 2017 19
Pipeline by Merck & Co Inc, H2 2017 19
Pipeline by Novartis AG, H2 2017 20
Pipeline by Trellis Bioscience Inc, H2 2017 20
Pipeline by Vakzine Projekt Management GmbH, H2 2017 21
Pipeline by VBI Vaccines Inc, H2 2017 21
Pipeline by Vical Inc, H2 2017 22
Dormant Projects, H2 2017 40

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 15
Number of Products by Stage and Routes of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 17
Number of Products by Stage and Molecule Types, H2 2017 17

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *